Sanofi Dupixent under USFDA priority review for adults with prurigo nodularis Ruchika Sharma31 May 2022 2:41 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not...
Sanofi Dupixent gets USFDA nod for eosinophilic esophagitis Ruchika Sharma22 May 2022 10:00 AM ISTEoE is a chronic inflammatory disease driven by type 2 inflammation that damages the esophagus and prevents it from working properly.
Sanofi Dupixent under USFDA priority review for eosinophilic esophagitis patients Ruchika Sharma5 April 2022 11:30 AM ISTParis: Sanofi has recently announced that the U.S. Food and Drug Administration (USFDA) has accepted for Priority Review the supplemental Biologics...
Sanofi targets eczema-treatment product Dupixent peak sales of over 13 billion euros Ruchika Sharma29 March 2022 1:21 PM ISTParis: French healthcare group Sanofi, which lagged rivals in the race for COVID-19 vaccines, raised on Tuesday its peak sales target for...
Setback: Sanofi to halt Dupixent Phase 3 trial MD Bureau21 Feb 2022 4:50 PM ISTParis: Sanofi has recently announced that the Phase 3 trial (CUPID STUDY B) evaluating Dupixent (dupilumab) in patients with chronic spontaneous...
Sanofi Dupixent under USFDA priority review for kids with atopic dermatitis Ruchika Sharma11 Feb 2022 12:23 PM ISTParis: Sanofi has recently announced that the U.S. Food and Drug Administration (USFDA) has accepted for Priority Review the supplemental Biologics...
Sanofi, Regeneron get CHMP recommendation for Dupixent approval to treat severe asthma with type 2 inflammation in kids Ruchika Sharma1 Feb 2022 10:00 AM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Medicines Agency's Committee for Medicinal Products for Human...
Dupilumab significantly improves itch and hives in chronic spontaneous urticaria patients: Study Hina Zahid5 Aug 2021 9:00 AM ISTUSA: Adding Dupixent (dupilumab) to standard-of-care antihistamines significantly reduced itch and hives in patients with moderate-to-severe chronic...
Sanofi wins EU approval for Dupixent for atopic dermatitis in children Ruchika Sharma1 Dec 2020 12:50 PM ISTDupixent is the only systemic medicine approved in the EU to treat these patients.
Speciality care, vaccines sale prompts Sanofi to raise outlook Ruchika Sharma31 Oct 2020 9:00 AM ISTParis: Sanofi raised its 2020 earnings guidance for the second time this year after posting slightly stronger-than-expected third-quarter results...
Sanofi Dupixent gets USFDA Breakthrough Therapy designation to treat eosinophilic esophagitis Ruchika Sharma16 Sept 2020 1:51 PM ISTParis: Drug major, Sanofi has recently secured Breakthrough Therapy designation from the U.S. Food and Drug Administration(USFDA) for its Dupixent (...
Dupilumab receives FDA's Breakthrough Therapy Status for eosinophilic esophagitis Medha Baranwal16 Sept 2020 7:46 AM ISTUSA: Dupilumab (Dupixent) has received the US FDA's Breakthrough Therapy designation for the treatment of eosinophilic esophagitis (EoE) in patients...
